These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27230663)

  • 1. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
    Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
    J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.
    Barrett JS; Bajaj G; McGuire J; Wu D; Spitsin S; Moorthy G; Zhao X; Tebas P; Evans DL; Douglas SD
    Curr HIV Res; 2014; 12(2):121-31. PubMed ID: 24862330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
    Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
    AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.
    Tebas P; Tuluc F; Barrett JS; Wagner W; Kim D; Zhao H; Gonin R; Korelitz J; Douglas SD
    PLoS One; 2011; 6(9):e24180. PubMed ID: 21931661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.
    Tebas P; Spitsin S; Barrett JS; Tuluc F; Elci O; Korelitz JJ; Wagner W; Winters A; Kim D; Catalano R; Evans DL; Douglas SD
    AIDS; 2015 May; 29(8):931-9. PubMed ID: 25915168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro.
    Wang X; Douglas SD; Lai JP; Tuluc F; Tebas P; Ho WZ
    J Neuroimmune Pharmacol; 2007 Mar; 2(1):42-8. PubMed ID: 18040825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective and anti-human immunodeficiency virus activity of minocycline.
    Zink MC; Uhrlaub J; DeWitt J; Voelker T; Bullock B; Mankowski J; Tarwater P; Clements J; Barber S
    JAMA; 2005 Apr; 293(16):2003-11. PubMed ID: 15855434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis.
    Martinez AN; Burmeister AR; Ramesh G; Doyle-Meyers L; Marriott I; Philipp MT
    J Neuroinflammation; 2017 Feb; 14(1):37. PubMed ID: 28202084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.
    Spitsin S; Tebas P; Barrett JS; Pappa V; Kim D; Taylor D; Evans DL; Douglas SD
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.
    Morita M; Kishi S; Ookura M; Matsuda Y; Tai K; Yamauchi T; Ueda T
    Curr Probl Cancer; 2017; 41(6):419-425. PubMed ID: 29061362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages.
    Wang X; Douglas SD; Song L; Wang YJ; Ho WZ
    J Neuroimmune Pharmacol; 2008 Dec; 3(4):257-64. PubMed ID: 18654860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
    Bergström M; Hargreaves RJ; Burns HD; Goldberg MR; Sciberras D; Reines SA; Petty KJ; Ogren M; Antoni G; Långström B; Eskola O; Scheinin M; Solin O; Majumdar AK; Constanzer ML; Battisti WP; Bradstreet TE; Gargano C; Hietala J
    Biol Psychiatry; 2004 May; 55(10):1007-12. PubMed ID: 15121485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.
    Spitsin S; Tuluc F; Meshki J; Ping Lai J; Tustin Iii R; Douglas SD
    Neuroimmunomodulation; 2013; 20(5):247-55. PubMed ID: 23921645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of Productively Infected Monocytes and Macrophages of Simian Immunodeficiency Virus-Infected Macaques.
    Avalos CR; Price SL; Forsyth ER; Pin JN; Shirk EN; Bullock BT; Queen SE; Li M; Gellerup D; O'Connor SL; Zink MC; Mankowski JL; Gama L; Clements JE
    J Virol; 2016 Jun; 90(12):5643-5656. PubMed ID: 27030272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
    Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
    Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced Simian Immunodeficiency Virus Replication in Macrophages of Sooty Mangabeys Is Associated with Increased Expression of Host Restriction Factors.
    Mir KD; Mavigner M; Wang C; Paiardini M; Sodora DL; Chahroudi AM; Bosinger SE; Silvestri G
    J Virol; 2015 Oct; 89(20):10136-44. PubMed ID: 26202248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research.
    Wu D; Paul DJ; Zhao X; Douglas SD; Barrett JS
    J Pharm Biomed Anal; 2009 Apr; 49(3):739-45. PubMed ID: 19167182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.
    Jin P; Deng S; Sherchan P; Cui Y; Huang L; Li G; Lian L; Xie S; Lenahan C; Travis ZD; Zhang JH; Gong Y; Tang J
    Neurotherapeutics; 2021 Jul; 18(3):1922-1938. PubMed ID: 34244927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions.
    Mothapo KM; Ten Oever J; Koopmans P; Stelma FF; Burm S; Bajramovic J; Verbeek MM; Rikkert MGO; Netea MG; Koopman G; van der Ven AJ
    J Neurovirol; 2017 Apr; 23(2):250-259. PubMed ID: 27882497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.